Zobrazeno 1 - 10
of 18
pro vyhledávání: '"David E. Morse"'
Autor:
Jogarao V. S. Gobburu, Edwin P. Rock, Cheng Yi Liang, Sophia Abraham, Nallaperumal Chidambaram, S. Leigh Verbois, David E. Morse, Janet X. Jiang, Shenghui Tang, Richard Pazdur, Robert Justice, Roshni Ramchandani, Vicki L. Goodman, Ramzi Dagher, Brian Booth, Kooros Mahjoob
Publikováno v:
Clinical Cancer Research. 13:1367-1373
Purpose: To describe the Food and Drug Administration (FDA) review and approval of sunitinib malate (Sutent). Sunitinib received regular approval for the treatment of gastrointestinal stromal tumor (GIST) after disease progression or intolerance to i
Autor:
Sophia Abraham, Robert C. Kane, Lilliam A. Rosario, Grant R. Williams, Kimberly Benson, David E. Morse, Yong-Cheng Wang, Richard Pazdur, Sean Bradley, Cheng Yi Liang, Atiqur Rahman, Anwar Goheer, Shwu-Luan Lee, John K. Leighton, Richard T. Lostritto, Jogarao V. S. Gobburu, S. Leigh Verbois, Ann T. Farrell, William D. McGuinn, Peter F. Bross, Margaret E. Brower
Publikováno v:
Clinical Cancer Research. 10:3954-3964
Purpose: Multiple myeloma is a malignant plasma cell disorder accounting for about 10% of hematological malignancies. Despite treatment advances, including hematopoietic stem-cell transplantation to facilitate administration of high-dose cytotoxic ch
Publikováno v:
Psychopharmacology. 104:244-248
The acoustic startle reflex was used to measure changes in sensorimotor reactivity in response to nicotine administration and cessation. Male rats received saline, 6 mg/kg/day or 12 mg/kg/day nicotine delivered subcutaneously by osmotic minipumps. Th
Autor:
Leigh Verbois, Ann T. Farrell, Robert Justice, Rajeshwari Sridhara, Bhupinder S. Mann, John R. Johnson, Sophia Abraham, David E. Morse, Richard Pazdur, Brian Booth, Josephine M. Jee, Sarah Pope, Kun He, Ravi Harapanhalli, Ramzi Dagher
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 13(8)
Purpose: To discuss vorinostat approval for treatment of cutaneous manifestations of advanced cutaneous T-cell lymphoma (CTCL). Experimental Design: Data from 1 single-arm, open-label, multicenter pivotal trial and 11 other trials submitted to suppor
Autor:
Maitreyee Hazarika, Robert M. White, Brian P. Booth, Yong-Cheng Wang, Doo Y. Lee Ham, Cheng Yi Liang, Atiqur Rahman, Jogarao V.S. Gobburu, Ning Li, Rajeshwari Sridhara, David E. Morse, Richard Lostritto, Patricia Garvey, John R. Johnson, Richard Pazdur
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 11(3)
Purpose: This report describes the data and analysis leading to the approval of pemetrexed (LY 231514, MTA, Alimta, Eli Lilly and Co., Indianapolis, IN) by the U.S. Food and Drug Administration (FDA) of a New Drug Application for the treatment of mal
Autor:
Peter F, Bross, Amy, Baird, Gang, Chen, Josephine M, Jee, Richard T, Lostritto, David E, Morse, Liliam A, Rosario, Gene M, Williams, Peiling, Yang, Atiqur, Rahman, Grant, Williams, Richard, Pazdur
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 9(12)
Patients with hormone-sensitive breast cancer who have responded to tamoxifen (TAM) may receive additional benefit from a second endocrine agent after progression or relapse after TAM therapy. Fulvestrant (FVT; Faslodex; i.m. injection, ICI 182,780;
Autor:
Robert Osterberg, Kenneth L. Hastings, Jeri El-Hage, John Leighton, David E. Morse, Abigail Jacobs
Publikováno v:
Toxicology and Applied Pharmacology. 190:91-92
Publikováno v:
SPIE Proceedings.
The Cryogenic InfraRed Radiance Instrumentation for Shuttle (CIRRIS 1A) instrument, successfully flown and operated on the Shuttle Discovery from 28 April to 6 May 1991, was designed to operate at supercritical helium temperatures. During flight, the
Publikováno v:
Annals of the New York Academy of Sciences. 648
Publikováno v:
Journal of Clinical Oncology. 25:14152-14152
14152 Background: Since 2001, 5 tyrosine kinase inhibitors (TKi’s; imatinib, erlotinib, sorafenib, sunitinib and dasatinib) have been approved for hematologic and solid tumor indications including, CML, ALL, GIST, RCC, pancreatic and NSCLC. While i